"Moderna's stock fell by more than 20% after the company reduced its 2025 revenue forecast by $1 billion, now expecting between $1.5 billion and $2.5 billion. The company is implementing cost-cutting plans to reduce expenses by $1 billion this year due to lower than expected sales of its vaccines. CEO Stéphane Bancel admitted that the company was overly optimistic about its respiratory syncytial virus forecasts, as demand for COVID and RSV shots decreased in 2024. Investors remain cautious about Moderna's future success despite an expansive pipeline, as the company faces challenges in the market for its new vaccines."